Biomarker testing can help match you with the treatment that may work best for your cancer
There are now more than 20 approved treatments that specifically target genetic drivers of lung cancer, which can be identified by biomarker testing.[1] In fact, medical guidelines now recommend that doctors order biomarker testing for patients with both early and advanced stage lung cancer. This is important because biomarker testing is the only way to know whether you might benefit from targeted therapy or in some cases, immunotherapy.
If you don’t have a biomarker that can be targeted with an approved therapy, testing can still help guide you to treatment options, such as chemotherapy or potential clinical trials evaluating promising new therapies.
[1] American Cancer Society. Targeted Drug Therapy for Non-Small Cell Lung Cancer. Available online at: https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell/targeted-therapies.html. Accessed on October 25, 2022.
